Compare Stocks: ADCT, AVBP, PRME, and GERN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADCT ADC Therapeutics	$1.52 -6.4%	$1.28	$0.78 ▼ $4.98	$193.42M	1.86	1.37 million shs	632,644 shs
AVBP ArriVent BioPharma	$15.92 +1.2%	$25.32	$11.36 ▼ $35.83	$786.22M	1.34	727,013 shs	305,485 shs
GERN Geron	$0.94 -2.5%	$1.32	$0.84 ▼ $2.01	$606.50M	0.61	13.84 million shs	24.16 million shs
PRME Prime Medicine	$5.27 -1.8%	$3.47	$2.67 ▼ $5.91	$958.22M	2.37	3.25 million shs	8.32 million shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADCT ADC Therapeutics	+1.90%	+6.86%	+27.89%	+43.05%	-63.81%
AVBP ArriVent BioPharma	+2.14%	-17.73%	-46.31%	-48.70%	-19.99%
GERN Geron	-15.78%	-16.51%	-22.52%	-28.05%	-24.34%
PRME Prime Medicine	+23.22%	+40.68%	+86.11%	+77.48%	+11.20%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADCT ADC Therapeutics	$1.52 -6.4%	$1.28	$0.78 ▼ $4.98	$193.42M	1.86	1.37 million shs	632,644 shs
AVBP ArriVent BioPharma	$15.92 +1.2%	$25.32	$11.36 ▼ $35.83	$786.22M	1.34	727,013 shs	305,485 shs
GERN Geron	$0.94 -2.5%	$1.32	$0.84 ▼ $2.01	$606.50M	0.61	13.84 million shs	24.16 million shs
PRME Prime Medicine	$5.27 -1.8%	$3.47	$2.67 ▼ $5.91	$958.22M	2.37	3.25 million shs	8.32 million shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADCT ADC Therapeutics	+1.90%	+6.86%	+27.89%	+43.05%	-63.81%
AVBP ArriVent BioPharma	+2.14%	-17.73%	-46.31%	-48.70%	-19.99%
GERN Geron	-15.78%	-16.51%	-22.52%	-28.05%	-24.34%
PRME Prime Medicine	+23.22%	+40.68%	+86.11%	+77.48%	+11.20%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADCT ADC Therapeutics	2.33	Hold	$5.00	215.46% Upside
AVBP ArriVent BioPharma	2.73	Moderate Buy	$24.56	50.10% Upside
GERN Geron	2.33	Hold	$3.75	281.10% Upside
PRME Prime Medicine	2.90	Moderate Buy	$7.47	37.76% Upside

Current Analyst Ratings Breakdown

Latest ADCT, AVBP, PRME, and GERN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/28/2026	GERN Geron	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Outperform	$5.00
10/28/2026	GERN Geron	Needham & Company LLC Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$4.00 ➝ $2.50
10/27/2026	AVBP ArriVent BioPharma	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$18.00 ➝ $30.00
10/26/2026	AVBP ArriVent BioPharma	Truist Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$21.00
10/26/2026	AVBP ArriVent BioPharma	Oppenheimer Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform	$25.00
10/21/2026	GERN Geron	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
10/20/2026	AVBP ArriVent BioPharma	B. Riley Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$45.00 ➝ $29.00
10/16/2026	AVBP ArriVent BioPharma	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$29.00
10/15/2026	ADCT ADC Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	AVBP ArriVent BioPharma	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/8/2026	AVBP ArriVent BioPharma	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$47.00 ➝ $27.00

(Data available from 10/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADCT ADC Therapeutics	$79.58M	2.54	N/A	N/A	($1.50) per share	-1.06
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	$7.44 per share	N/A
GERN Geron	$204.56M	3.09	N/A	N/A	$0.35 per share	2.81
PRME Prime Medicine	$4.07M	241.54	N/A	N/A	$0.67 per share	8.10

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADCT ADC Therapeutics	-$142.62M	-$0.66	N/A	N/A	N/A	-121.77%	N/A	-32.74%	11/10/2026 (Estimated)
AVBP ArriVent BioPharma	-$166.31M	-$3.62	N/A	N/A	N/A	N/A	-50.26%	-46.66%	11/16/2026 (Estimated)
GERN Geron	-$83.50M	-$0.11	N/A	16.40	N/A	-34.17%	-24.48%	-10.30%	11/4/2026 (Estimated)
PRME Prime Medicine	-$201.14M	-$1.06	N/A	N/A	N/A	-4,613.11%	-188.27%	-59.11%	N/A

Latest ADCT, AVBP, PRME, and GERN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/16/2026	Q3 2026	AVBP ArriVent BioPharma	-$1.04	N/A	N/A	N/A	$0.80 million	N/A
11/10/2026	Q3 2026	ADCT ADC Therapeutics	-$0.21	N/A	N/A	N/A	$18.69 million	N/A
11/4/2026	Q3 2026	GERN Geron	-$0.01	N/A	N/A	N/A	$60.36 million	N/A
8/13/2026	Q2 2026	ADCT ADC Therapeutics	-$0.2160	-$0.11	+$0.1060	-$0.11	$18.89 million	$19.25 million
8/12/2026	Q2 2026	AVBP ArriVent BioPharma	-$0.9873	-$1.05	-$0.0627	-$1.05	N/A	N/A
8/6/2026	Q2 2026	PRME Prime Medicine	-$0.24	-$0.24	N/A	-$0.24	$4.40 million	$1.15 million
8/5/2026	Q2 2026	GERN Geron	-$0.0089	-$0.02	-$0.0111	-$0.02	$55.30 million	$57.48 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADCT ADC Therapeutics	N/A	N/A	N/A	N/A	N/A
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	N/A
GERN Geron	N/A	N/A	N/A	N/A	N/A
PRME Prime Medicine	$1.45	26.66%	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADCT ADC Therapeutics	N/A	3.03	2.97
AVBP ArriVent BioPharma	N/A	14.16	14.16
GERN Geron	0.55	6.91	5.16
PRME Prime Medicine	N/A	3.05	3.05

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADCT ADC Therapeutics	41.10%
AVBP ArriVent BioPharma	9.48%
GERN Geron	73.71%
PRME Prime Medicine	70.37%

Insider Ownership

Company	Insider Ownership
ADCT ADC Therapeutics	5.10%
AVBP ArriVent BioPharma	8.58%
GERN Geron	1.71%
PRME Prime Medicine	16.04%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADCT ADC Therapeutics	191	127.67 million	121.16 million	Optionable
AVBP ArriVent BioPharma	77	49.31 million	45.08 million	Optionable
GERN Geron	258	642.47 million	631.49 million	Optionable
PRME Prime Medicine	146	181.38 million	152.28 million	Optionable

ADCT, AVBP, PRME, and GERN Headlines

Recent News About These Companies

Prime Medicine, Inc. (PRME) Surges 23.2%: Is This an Indication of Further Gains?

October 29 at 4:46 AM | zacks.com

PRME, BEAM, EDIT, NTLA, CRSP stocks gain as FDA signals faster route for patient-specific gene edits

October 28 at 5:34 PM | msn.com

Prime Medicine Shares Hit 52-Week High After Dosing Begins in PM577a Trial

October 28 at 2:59 PM | marketscreener.comM

Prime Medicine (NASDAQ:PRME) Reaches New 1-Year High - Here's What Happened

October 28 at 12:40 PM | marketbeat.com

Prime Medicine (NASDAQ:PRME) Stock Price Up 7.1% - Here's What Happened

October 27 at 12:19 PM | marketbeat.com

Prime Medicine (NASDAQ:PRME) Stock Price Down 8.1% - Here's Why

October 23, 2026 | marketbeat.com

Prime Medicine, Inc. (PRME) - What Are Brokerages Thinking About This Stock?

October 17, 2026 | marketbeat.com

Prime Drink Group Announces Subscription Receipt Financing and Closing of Second Tranche of Private Placement of Units

October 15, 2026 | businesswire.com

Prime Medicine (NASDAQ:PRME) Stock Jumps 8.5% - Time to Buy?

October 15, 2026 | marketbeat.com

Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why

October 12, 2026 | zacks.com

Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why

October 12, 2026 | finance.yahoo.com

Prime Medicine (NASDAQ:PRME) Stock Falls 7.6% - Here's Why

October 8, 2026 | marketbeat.com

Prime Medicine (NASDAQ:PRME) Stock Jumps 3.5% - Here's Why

October 7, 2026 | marketbeat.com

Prime Medicine, Inc. Doses First Patient In Global Phase 1/2 Clinical Trial Of PM577a For H1069Q-Mutated Wilson Disease

October 6, 2026 | marketscreener.comM

Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX) and Prime Medicine, Inc. (PRME)

October 6, 2026 | theglobeandmail.com

Prime Medicine (NASDAQ:PRME) Shares Gap Up - Here's Why

October 6, 2026 | marketbeat.com

Prime Medicine Doses First Patient in Trial of Investigational Wilson Disease Treatment

October 5, 2026 | marketscreener.comM

Prime Medicine Doses First Patient in Global Phase 1/2 Trial of PM577a for Wilson Disease and Receives FDA Rare Pediatric Disease Designation

October 5, 2026 | quiverquant.comQ

Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease

October 5, 2026 | globenewswire.com

What kind of company is Prime Medicine (PRME)? — A gene-editing company where funding outlooks and data timelines "overlap"

October 3, 2026 | note.comN

Prime Medicine (NASDAQ:PRME) Cut to "Sell" at Wall Street Zen

October 3, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADCT, AVBP, PRME, and GERN Company Descriptions

ADC Therapeutics NYSE:ADCT

$1.52 -0.10 (-6.42%)

As of 03:35 PM Eastern

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

ArriVent BioPharma NASDAQ:AVBP

$15.92 +0.19 (+1.23%)

As of 03:35 PM Eastern

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Geron NASDAQ:GERN

$0.94 -0.02 (-2.53%)

As of 03:36 PM Eastern

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Prime Medicine NASDAQ:PRME

$5.26 -0.10 (-1.77%)

As of 03:36 PM Eastern

We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology. Genetic mutations implicated in disease are diverse and can range from errors of a single base, known as point mutations, to errors that extend beyond a single base, such as insertions, deletions, duplications, or combinations thereof. We believe the ability to alter the human genome at the foundational level may confer the greatest therapeutic impact on human disease. Gene editing, including platforms such as Prime Editing, is a novel technology that is not yet clinically validated for human therapeutic use. Over the last decade, the field of genetic medicine has evolved tremendously, with groundbreaking advances in gene therapy, cell therapy, RNA therapy, and, more recently, gene editing. These technologies represent dramatic advancements for genetic therapies, but lack the versatility to precisely and efficiently correct the diverse range of mutations or DNA alterations implicated in disease. Prime Medicine was co-founded by a world-renowned leader in the field of gene editing, David Liu, Ph.D. Dr. Liu was joined as co-founder by Andrew Anzalone, M.D., Ph.D., who conceived of and developed Prime Editing technology. Drawn by the promise of Prime Editing’s ability to transform the field of gene editing, we have assembled a diverse team that has grown to more than 150 people as of September 30, 2022. There are no current plans for Dr. Liu to be an officer or director of our company following this offering. He is expected to continue to provide consulting services to us pursuant to a consulting agreement, which has a current term that runs through September 2025 and accommodates a previous commitment with respect to Beam Therapeutics Inc., which could result in or may create the appearance of a conflict of interest. He is also expected to retain his position and affiliation with the Broad Institute, Inc., Howard Hughes Medical Institute and Harvard University. On September 20, 2022, we achieved a major milestone as the United States Patent and Trademark Office, or the USPTO, issued U.S. Patent 11,447,770, or the ‘770 Patent, covering methods of using Prime Editors. The Broad Institute, Inc., or Broad Institute, prepared, filed and prosecuted the ‘770 Patent. While Broad Institute is the owner of the ‘770 Patent, it is exclusively licensed to us under the terms of the license agreement with Broad Institute. The ‘770 Patent is the first issued Prime Editing patent in our licensed patent portfolio and we believe it will be instrumental in protecting our Prime Editing platform and pipeline of gene editing programs. We believe our in-licensed and company-owned Prime Editing technology has transformative potential that could change the course of how disease is treated and overcome the challenges associated with current genetic therapies. We in-license our Prime Editing technology pursuant to a license agreement with Broad Institute. In addition, the license agreement grants us certain rights and licenses under certain patent rights Broad Institute owns or controls, including a license to the ‘770 Patent, which covers Prime Editing technology and expires in 2040. The licenses are limited to the field of prevention or treatment of human disease, and most licenses granted to us under the license agreement are further limited to the prevention or treatment of human disease by editing (including modifying or converting) or targeting DNA ex vivo, in vivo, or through xeno transplantation methods, which we refer to as the Prime Broad Field. We were incorporated under the laws of the State of Delaware in September 2019 under the name Prime Medicine, Inc. Our principal executive offices are located at 21 Erie Street, Cambridge, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ADCT, AVBP, PRME, and GERN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ADCT, AVBP, PRME, and GERN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ADCT, AVBP, PRME, and GERN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADCT, AVBP, PRME, and GERN Company Descriptions

ADC Therapeutics NYSE:ADCT

ArriVent BioPharma NASDAQ:AVBP

Geron NASDAQ:GERN

Prime Medicine NASDAQ:PRME

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ADCT, AVBP, PRME, and GERN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ADCT, AVBP, PRME, and GERN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ADCT, AVBP, PRME, and GERN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADCT, AVBP, PRME, and GERN Company Descriptions

ADC Therapeutics NYSE:ADCT

ArriVent BioPharma NASDAQ:AVBP

Geron NASDAQ:GERN

Prime Medicine NASDAQ:PRME

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools